Found Health

Found’s pricing is easiest to understand when separated by plan. For self‑pay, the legacy CORE membership is $129 per 30 days (with a 6‑month prepay option at $594), while PLUS self‑pay is $199 per 30 days. With insurance, PLUS is advertised at $39/mo or $199 annually (~$17/mo). Medication billing differs: the Generics (non‑GLP‑1) plan can include certain orals when filled through a Found‑facilitated pharmacy; the Compounded GLP‑1 plan includes the compounded medication in its cycle price; the Branded GLP‑1 plan bills brand medication separately (via insurance, cash pay, or manufacturer channels). This segmentation is clear and compares favorably to competitors that obscure what membership actually covers.Policy caveats matter: membership fees are refundable only within three days of purchase or before the first consult; renewals are non‑refundable, and meds/lab kits are non‑returnable. Those constraints, plus auto‑renewal, can increase total cost if you don’t cancel ahead of your cycle. Overall we score pricing high for transparency across plan families but dock points for limited refund flexibility and potential multi‑line billing (membership + medication + visit copays).

We assessed clinical posture via published materials and disclosures. Found’s model employs licensed clinicians with discretion over prescribing and provides clear risk language for GLP‑1s and orals. The library spans >10 medications, and content emphasizes individualized protocols rather than one‑size dosing. Found cites internal outcomes and a 66,000‑person analysis suggesting telehealth can deliver clinically meaningful results. We view this breadth and documentation as a strength.Quality trade‑offs are typical of mail‑order fulfillment. Terms disclose that third‑party pharmacies may not use child‑resistant packaging and that compounded medications are not FDA‑approved and have state‑by‑state limits. These are appropriate warnings but remind us to temper expectations on standardization. Net: strong evidence‑aligned program design, with reasonable risk‑benefit framing and appropriate disclosures.

Onboarding begins with a brief intake and MetabolicPrint™ assessment, then clinician review, medication selection, and shipping. Found’s site indicates delivery in 3–5 days for most medications after prescription processing. In our walkthroughs, the steps are intuitive and mobile‑first. Where timelines can stretch is coverage verification for branded GLP‑1s, or when inventory constraints affect fulfillment. The messaging‑first care model streamlines quick questions but may lengthen time for complex discussions if you prefer synchronous visits.Plan eligibility nuances (e.g., self‑pay vs insurance, what’s included) are well explained in offer terms and help avoid surprises. We award a strong score for clarity and speed promises, with a small deduction for the real‑world variability that accompanies insurer prior authorizations and national GLP‑1 supply swings.

Found offers a broad toolkit across GLP‑1 and non‑GLP‑1 therapies, including semaglutide (Wegovy/Ozempic), tirzepatide (Zepbound/Mounjaro), liraglutide (Saxenda/Victoza), plus orals like metformin, topiramate, and Contrave. The program explicitly distinguishes between compounded and branded options and states that prescribing is based on clinician judgment and eligibility. The public price tiles for branded GLP‑1s help patients frame expectations when paying cash.Limitations: compounded drugs are not FDA‑approved and may not be offered everywhere; branded supply and insurer coverage vary. Despite these constraints, the breadth of choices and clear plan design push this near the top of the category.

Found communicates an expected 3–5‑day delivery window for most medications post‑prescription. That commitment is repeated across the site and onboarding content. Packaging and fulfillment are handled by third‑party pharmacies; terms note packages may not be child‑resistant and that medications are non‑returnable. We appreciate the consistent shipping expectation setting and the disclosures around fulfillment limits.In high‑demand periods, any GLP‑1 provider can see delays. Found’s plan diversification (e.g., generics vs branded GLP‑1s) provides alternatives if one path stalls. We score 8/10: strong on clarity and typical performance, with reasonable caveats disclosed.

Support is accessible via app, email, and scheduled consults. Public review dashboards show the company actively responds (notably a high response rate to negative reviews) and that many customers praise coaching and provider attentiveness. We also see critical feedback regarding charges across membership, visits, and meds, and some frustration tied to changing visit cadence requirements. This pattern is consistent with subscription‑based healthcare models as they evolve policy and utilization controls.Net: helpful day‑to‑day guidance with mixed experiences around billing communications and policy updates. We award 7/10—above average responsiveness with room to tighten expectation setting around fees and follow‑up scheduling.

Found’s site and app are polished, with clear plan cards, medication tiles, and an insurance coverage checker. The education hub and medication pages offer plain‑language explanations and safety links, and the membership pages outline inclusions succinctly. The primary friction points we note are less about UI and more about policy comprehension (renewals, refunds, what’s included vs. separate billing) that require careful reading of the offer terms—hardly unique to Found. Overall UX is modern, coherent, and patient‑forward.